Overview

MeSH Major

Breast Neoplasms

DNA Mutational Analysis

Drug Resistance, Neoplasm

abstract

Mutational burden in heavily treated trastuzumab-resistant Her2-positive metastatic breast cancer is highly variable and not directly correlated with outcome. Activation of the MAPK/ERK pathway through mutations in EGFR, BRAF or KIT may mediate resistance to trastuzumab.